Cayuga Biotech, Inc.


Cayuga Biotech is dedicated to harnessing the body's innate ability to halt bleeding and promote healing through innovative biomimetic therapies. The company develops proprietary science-based solutions, including polyphosphate-based therapies, to address significant unmet needs in hemorrhage control and bleeding disorders. Their mission is to improve survival outcomes in life-threatening hemorrhage and advance treatment options for bleeding disorders.

Industries

biotechnology
health-care
medical
medical-device

Nr. of Employees

small (1-50)

Cayuga Biotech, Inc.

500 Eighth Avenue, Front 3, # 1596, New York, NY 10018


Products

Optimized polyphosphate-derived systemic injectable hemostatic therapy (lead program, late preclinical)

An optimized formulation of short-chain polyphosphate complexed with nanoparticles developed for systemic administration to accelerate hemostatic control in acute major hemorrhage (intended for non-compressible bleeding sites).

Discovery-stage polyphosphate-derived composition for inherited bleeding disorders

A discovery-stage composition based on polyphosphate chemistry being explored as a potential treatment approach for inherited bleeding disorders.


Services

Engagements for investment, development partnerships, licensing discussions and collaborative development of hemorrhage and bleeding-disorder therapeutics.

Expertise Areas

  • Hemostasis and hemorrhage therapeutics
  • Preclinical hemorrhage model testing
  • Nanoparticle–polymer formulation for systemic delivery
  • Translational medicine and drug discovery
  • Show More (4)

Key Technologies

  • Polyphosphate-based therapeutics
  • Silica nanoparticle–polymer complexation
  • Systemic injectable drug delivery
  • In vitro coagulation assays (clotting kinetics)
  • Show More (4)

News & Updates

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.